Back to Results

Nu Med Plus Inc (NUMD)

Nu Med Plus Inc. is a healthcare company focused on medical device development and commercialization. The company works on nitric oxide-based technologies, including a formulation that generates nitric oxide, a bedside delivery system for hospital use, a clinical unit designed for medical clinics and rehabilitation centers, and a mobile rechargeable device for delivering nitric oxide gas. Its portfolio also includes a nitric oxide system intended for research applications and a portable rechargeable device for inhaled nitric oxide delivery. Nu Med Plus was incorporated in 2011 and is based in Port Jefferson, New York. Its common stock is quoted on OTC Markets under the ticker NUMD.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-NUMD
$0.022
-6.1% Downside
Fair
Not available
Not available
Fair
0.0%
November 9, 2026
1.922 M
2.139 M
10.4%
35.4%
-1,113.6
248.8%
Valuation • Fair Value

Nu Med Plus Inc (OTC-NUMD) Fair Value by Valuation Model

Review the available estimates for Nu Med Plus Inc (OTC-NUMD), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.022

Estimated downside of 6.1% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.022

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Nu Med Plus Inc (OTC-NUMD) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Nu Med Plus Inc (OTC-NUMD)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Nu Med Plus Inc (OTC-NUMD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nu Med Plus Inc (OTC-NUMD)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-1,113.6

Lower score that deserves closer risk review.

FCF / Net Income

248.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nu Med Plus Inc (OTC-NUMD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nu Med Plus Inc (OTC-NUMD)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 9, 2026

Days to Earnings

48

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Nu Med Plus Inc (OTC-NUMD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Nu Med Plus Inc (OTC-NUMD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Nu Med Plus Inc (OTC-NUMD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Nu Med Plus Inc (OTC-NUMD) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Nu Med Plus Inc (OTC-NUMD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nu Med Plus Inc (OTC-NUMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Nu Med Plus Inc (OTC-NUMD) Stock FAQ

Data-supported answers about Nu Med Plus Inc (OTC-NUMD), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.022
Estimated downside 6.1%
Valuation Rating
Overvalued
Estimated downside of 6.1%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Nu Med Plus Inc (OTC-NUMD) is $0.022. This implies an estimated downside of 6.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.1% versus the current market price.

The current financial health read for Nu Med Plus Inc (OTC-NUMD) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nu Med Plus Inc (OTC-NUMD) is November 9, 2026.

The latest available data indicates no current dividend yield for Nu Med Plus Inc (OTC-NUMD).

The current market capitalization listed for Nu Med Plus Inc is 1.922 M.

The current enterprise value listed for Nu Med Plus Inc is 2.139 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nu Med Plus Inc is OTC-NUMD, and the stock is listed on OTC Markets.

Nu Med Plus Inc (OTC-NUMD) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Nu Med Plus Inc is 10.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nu Med Plus Inc is 35.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B